Page last updated: 2024-11-13
gsk2245035
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
GSK2245035: a Toll-like receptor 7 agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 44623937 |
| CHEMBL ID | 4297492 |
| SCHEMBL ID | 565847 |
| MeSH ID | M000612681 |
Synonyms (23)
| Synonym |
|---|
| SCHEMBL565847 |
| 6-amino-2-{[(1s)-1-methylbutyl]oxy}-9[5-(1-piperidinyl) pentyl]-7,9-dihydro-8h-purin-8-one |
| 6-amino-2-{[(1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-one |
| LFMPVTVPXHNXOT-HNNXBMFYSA-N |
| 6-amino-2-{[(1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl) pentyl]-7,9-dihydro-8h-purin-8-one |
| 6-amino-2-[(2s)-pentan-2-yloxy]-9-[5-(piperidin-1-yl)pentyl]-8,9-dihydro-7h-purin-8-one |
| gtpl9254 |
| gsk2245035 |
| compound 32 [pmid: 26861551] |
| gsk-2245035 |
| unii-5l3sx16qbq |
| 5L3SX16QBQ , |
| 8h-purin-8-one, 6-amino-7,9-dihydro-2-((1s)-1-methylbutoxy)-9-(5-(1-piperidinyl)pentyl)- |
| 1207629-49-9 |
| AKOS032954203 |
| CS-0065520 |
| HY-118250 |
| 6-amino-2-[(2s)-pentan-2-yl]oxy-9-(5-piperidin-1-ylpentyl)-7h-purin-8-one |
| F3409-0744 |
| (s)-6-amino-2-(pentan-2-yloxy)-9-(5-(piperidin-1-yl)pentyl)-7,9-dihydro-8h-purin-8-one |
| CHEMBL4297492 |
| MS-26512 |
| 6-amino-7,9-dihydro-2-[(1s)-1-methylbutoxy]-9-[5-(1-piperidinyl)pentyl]-8h-purin-8-one |
Research Excerpts
Overview
GSK2245035 is a novel selective TLR7 agonist in pharmaceutical development.
| Excerpt | Reference | Relevance |
|---|---|---|
| "GSK2245035 is a novel selective TLR7 agonist in pharmaceutical development." | ( Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: A randomized trial. Ellis, AK; Lee, LA; Powley, W; Quint, D; Tsitoura, DC, 2017) | 1.44 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Adverse events (AEs) including cytokine release syndrome AEs (CytoRS-AEs) and nasal symptoms were assessed." | ( Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: A randomized trial. Ellis, AK; Lee, LA; Powley, W; Quint, D; Tsitoura, DC, 2017) | 0.72 |
Dosage Studied
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1345471 | Human TLR7 (Toll-like receptor family) | 2016 | Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5 | Discovery of 6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 17.57
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.57) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (60.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 2 (40.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||